Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA

The treatment or prevention of bleeding in patients with hemophilia A relies on replacement therapy with different factor VIII (FVIII)-containing products or on the use of by-passing agents, i.e., activated prothrombin complex concentrates or recombinant activated factor VII. Emerging approaches inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Russick, Jules, Delignat, Sandrine, Milanov, Peter, Christophe, Olivier, Boros, Gábor, Denis, Cécile V., Lenting, Peter J., Kaveri, Srinivas V., Lacroix-Demazes, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109737/
https://www.ncbi.nlm.nih.gov/pubmed/31289204
http://dx.doi.org/10.3324/haematol.2018.210583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109737/
https://www.ncbi.nlm.nih.gov/pubmed/31289204
http://dx.doi.org/10.3324/haematol.2018.210583

Ejemplares similares